Orchard Therapeutics Expands Gene Therapy MfgBy
Orchard Therapeutics, a Foster City, California-based clinical-stage biotechnology company, has opened a second facility for technical operations that support development and validation of processes and controls for the manufacture of the company’s ex-vivo lentiviral gene-therapy products.
In combination with the existing Foster City site, Orchard says the new facility in the San Francisco Bay area quadruples its laboratory footprint for technical operations.
Orchard’s pipeline includes clinical and preclinical stage autologous, ex-vivo lentiviral gene therapies for primary immune deficiencies and inherited metabolic disorders. The company’s lead product, OTL-101, for treating adenosine deaminase severe combined immunodeficiency is in late-stage development, and Orchard says is anticipated to progress to a biological license application with the US Food and Drug Administration in 2018.
Source: Orchard Therapeutics